Beijing Xinbo Technology Trading Co., Ltd.

Tarceva (erlotinib hydrochloride tablets) is indicated as erlotinib monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one previous chemotherapy regimen. In two multi-center, randomized, placebo-controlled phase III trials, the results showed that erlotinib combined with platinum-containing chemotherapy regimens (carboplatin + paclitaxel or gemcitabine + cisplatin) as first-line treatment for patients with locally advanced or metastatic disease is more effective than monotherapy alone. Platinum-containing chemotherapy has no added clinical benefit and is not recommended as first-line treatment in these conditions. Erlotinib single agent can be used for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer who have stable disease after one cycle of platinum-based first-line chemotherapy. This indication is based on the results of a randomized, double-blind, placebo-controlled study [see Clinical Trials]. No clinical study data are available comparing treatment with erlotinib in the absence of progression versus progression after first-line chemotherapy. Clinical research on this product for first-line treatment of mutant populations is ongoing. It is recommended that treating doctors use this product together with Tarceva. It will undoubtedly become a new discovery in the field of curing lung cancer patients. Different from previous years, this year's Lung Cancer Awareness Month uses the drama "Cheers for Life" adapted from real people and true events to demonstrate patients' optimism and never shrink back in the face of the disease. The emergence of targeted drugs provides a new possibility for conquering lung cancer.